Otros idiomas GSK plc

Acciones

GSK

GB00BN7SWP63

Farmacéuticos

Mercado cerrado - London S.E. Otros sitios de cotización 17:35:14 17/07/2026			Variación 5 días	Varia. 1 de enero.
1.916,50 ^GBX	-2,02 %		-2,29 %	+5,04 %

17/07	El FTSE 100 sube impulsado por las energéticas y las 'utilities'; Burnham, nuevo líder del Partido Laborista	RE
17/07	Las acciones europeas que cotizan en EE. UU. como ADR caen este viernes	MT

Otros idiomas

17/07	UK's FTSE 100 rises on utilities, energy boost; Burnham becomes Labour Party leader
17/07	Schwach - Erneute Abgaben im Technologie-Sektor
17/07	European Equities Traded in the US as American Depositary Receipts Decline Friday
17/07	Global markets live: Netflix, Coca-Cola, Apple, Google, SpaceX…
17/07	WOCHENVORSCHAU/27. Juli bis 1. August (31. KW)
17/07	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investors Retreat From Chipmaker Stocks
17/07	GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment
17/07	Jefferies belässt GSK auf 'Buy' - Ziel 2500 Pence
17/07	Schwach - Abverkauf im Technologie-Sektor geht weiter
17/07	GSK stellt Entwicklung von Medikament gegen chronischen Husten ein
17/07	FTSE 100 bucks European AI stock selloff
17/07	GSK s'enfonce après une forte déception autour du camlipixant
17/07	UK's FTSE 100 flat as energy gains offset banks; Burnham set to become prime minister
17/07	GSK Stops Camlipixant Program in Refractory Chronic Cough After Phase 3 Data
17/07	GSK Ends Camlipixant Program for Chronic Cough on Limited Efficacy
17/07	Aktien Europa: Schwache Halbleiterwerte und Inflationssorgen belasten
17/07	GSK ends camlipixant research in RCC as trials show "limited efficacy"
17/07	WINNERS & LOSERS: Vega ups Vodafone stake; GSK drug trial disappoints
17/07	Gsk plc Provides Update on Calm-1 and Calm-2 Phase III Trials for Camlipixant in Refractory Chronic Cough
17/07	GSK Stops Development of Drug Candidate for Chronic Cough
17/07	GSK stops development of chronic cough drug after late-stage trial miss
17/07	GSK : provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)
16/07	India's Serum Institute partners with Gates MRI to make experimental TB vaccine
15/07	GSK boucle le rachat de Nuvalent
15/07	GSK Completes $10.6 Billion Acquisition of Nuvalent